Emibetuzumab Explained

Emibetuzumab (INN[1]) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer.[2] It is in phase II trials for patients with NSCLC[3]

This drug was developed by Eli Lilly & Company.

References

  1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 . WHO Drug Information . 28 . 2 . 2014 .
  2. http://www.ama-assn.org/resources/doc/usan/x-pub/emibetuzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Emibetuzumab
  3. Web site: Camidge DR, Moran T, Demedts I, Grosch H, Di Mercurio JP, Mileham KF, Molina JR, Juan Vidal O, Bepler G, Goldman JW, Lewanski C . 6 . A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC. .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Emibetuzumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.